INTEGRATED SAFETY ANALYSIS OF FILGOTINIB TREATMENT FOR RHEUMATOID ARTHRITIS FROM 7 CLINICAL TRIALS

被引：7
|
作者：
Genovese, M. C. [1 ]
Winthrop, K. [2 ]
Tanaka, Y. [3 ]
Takeuchi, T. [4 ]
Kivitz, A. [5 ]
Matzkies, F. [6 ]
Ye, L. [6 ]
Jiang, D. [6 ]
Guo, Y. [6 ]
Bartok, B. [6 ]
Besuyen, R. [7 ]
Burmester, G. R. [8 ]
Gottenberg, J. E. [9 ]
机构：
[1] Stanford Univ, Stanford, CA 94305 USA
[2] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[3] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka, Japan
[4] Keio Univ, Sch Med, Tokyo, Japan
[5] Altoona Ctr Clin Res, Duncansville, PA USA
[6] Gilead Sci Inc, Foster City, CA USA
[7] Galapagos BV, Leiden, Netherlands
[8] Charite, Berlin, Germany
[9] Strasbourg Univ Hosp, Strasbourg, France
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
GLPG0634/GS-6034; INHIBITOR;
D O I：
10.1136/annrheumdis-2020-eular.267
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0202
引用
收藏
页码：320 / 321
页数：2
相关论文
共 50 条
  • [1] Integrated safety analysis of filgotinib treatment for rheumatoid arthritis from seven clinical trials
    Nash, P.
    Loftus, E.
    Genovese, M.
    Winthrop, K.
    Tanaka, Y.
    Takeuchi, T.
    Kivitz, A.
    Matzkies, F.
    Ye, L.
    Jiang, D.
    Guo, Y.
    Bartok, B.
    Besuyen, R.
    Burmester, G.
    Gottenberg, J-E
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 130 - 130
  • [2] Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years
    Ishiguro, Naoki
    Tanaka, Yoshiya
    Matsubara, Tsukasa
    Atsumi, Tatsuya
    Amano, Koichi
    Sugiyama, Eiji
    Yamaoka, Kunihiro
    Winthrop, Kevin
    Kivitz, Alan
    Burmester, Gerd R.
    Gottenberg, Jacques-Eric
    Genovese, Mark C.
    Matzkies, Franziska
    Guo, Ying
    Jiang, Deyuan
    Bartok, Beatrix
    Pechonkina, Alena
    Kondo, Akira
    Besuyen, Robin
    Takeuchi, Tsutomu
    MODERN RHEUMATOLOGY, 2023, 33 (01) : 64 - 72
  • [3] Safety of filgotinib in rheumatoid arthritis
    Thorley, Jennifer
    LANCET RHEUMATOLOGY, 2024, 6 (07): : E421 - E421
  • [4] Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials
    Bykerk, V. P.
    Cush, J.
    Winthrop, K.
    Calabrese, L.
    Lortholary, O.
    de Longueville, M.
    van Vollenhoven, R.
    Mariette, X.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (01) : 96 - 103
  • [5] Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
    Combe, Bernard
    Besuyen, Robin
    Gomez-Centeno, Antonio
    Matsubara, Tsukasa
    Sancho Jimenez, Juan Jose
    Yin, Zhaoyu
    Buch, Maya H.
    RHEUMATOLOGY AND THERAPY, 2023, 10 (01) : 35 - 51
  • [6] Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
    Bernard Combe
    Robin Besuyen
    Antonio Gómez-Centeno
    Tsukasa Matsubara
    Juan José Sancho Jimenez
    Zhaoyu Yin
    Maya H. Buch
    Rheumatology and Therapy, 2023, 10 : 35 - 51
  • [7] Filgotinib for the treatment of rheumatoid arthritis
    Taylor, Peter C.
    Azeez, Maha Abdul
    Kiriakidis, Serafim
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (10) : 1181 - 1187
  • [8] Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials
    Tanaka, Yoshiya
    Kavanaugh, Arthur
    Wicklund, Jason
    McInnes, Iain B.
    MODERN RHEUMATOLOGY, 2022, 32 (01) : 1 - 11
  • [9] Leflunomide: Efficacy and safety in clinical trials for the treatment of rheumatoid arthritis
    Schiff, MH
    Strand, V
    Oed, C
    Loew-Friedrich, I
    DRUGS OF TODAY, 2000, 36 (06): : 383 - 394
  • [10] Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights
    Raimondo, Maria Gabriella
    Biggioggero, Martina
    Coletto, Lavinia Agra
    Ramming, Andreas
    Caporali, Roberto
    Favalli, Ennio Giulio
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (06) : 661 - 670
12345